Laurie Stelzer
Director/Board Member bij PMV PHARMACEUTICALS, INC.
Vermogen: - $ op 31-03-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
David Mack | M | 62 | 11 jaar | |
Jeffrey Henderson | M | 59 | 9 jaar | |
Russell Cox | M | 60 | 9 jaar | |
Cameron Turtle | M | 34 | 1 jaar | |
Carol Gallagher | M | 59 | 2 jaar | |
Michael Carulli | M | 74 | 4 jaar | |
Arnold Levine | M | 84 | 11 jaar | |
Richard Heyman | M | 66 | 4 jaar | |
Amit Munshi | M | 56 |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | - |
Deepika Jalota | M | 48 | 5 jaar | |
Scott Burrows | M | 47 | 1 jaar | |
Kirsten Flowers | F | 49 | 2 jaar | |
Heidy Abreu King-Jones | F | 41 | 1 jaar | |
Brian Goodman | M | - |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | - |
Michael Henderson | M | 34 | 1 jaar | |
Bernadette Connaughton | F | 65 | 6 jaar | |
Charles Baum | M | 65 | 3 jaar | |
Peter Harwin | M | 38 | 1 jaar | |
Tomas Kiselak | M | 38 | 1 jaar | |
Timothy J. Smith | M | - | 3 jaar | |
Tyler Jacks | M | 63 | 12 jaar | |
Robert Ticktin | M | 62 | - | |
Ciaran Lawlor | M | - |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | 3 jaar |
Shibu Sleeba | M | - | 4 jaar | |
Laura De Leon | F | - | 5 jaar | |
Crystal Zuckerman | F | - | 4 jaar | |
Mira Huyghe | F | - | 1 jaar | |
Joshua Friedman | M | - | 1 jaar | |
Marc Fellous | M | - | 2 jaar | |
Deanna Nguyen | M | - | 1 jaar | |
Lauren Harshman | F | - | 3 jaar | |
Amy Marinne Fox | F | - | 4 jaar | |
Lamine Mbow | M | - | 3 jaar | |
Steve Knowles | M | - | 6 jaar | |
Paul Fehlner | M | 61 | 1 jaar | |
Mark Mckenna | M | 48 | - | |
Binh Vu | M | 56 | - | |
Scott W. Rowlinson | M | 56 | 10 jaar | |
Jeffrey Albers | M | 52 | 1 jaar | |
Matt Roden | M | 53 |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | 1 jaar |
Morana Jovan-Embiricos | M | 57 |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | - |
Brian Connolly | M | - | 1 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 100 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Laurie Stelzer
- Persoonlijk netwerk